Screening for general anxiety disorders in postmenopausal women with symptomatic pelvic organ prolapse. (2nd January 2018)

• Record Type: Journal Article
• Authors: Ai, F.; Deng, M.; Mao, M.; Xu, T.; Zhu, L.
• Is Part Of: Climacteric. Volume 21:Number 1(2018)
• Page Start: 35
• Page End: 39
• Publication Date: 2018-01-02
• Subjects: General anxiety disorders -- postmenopausal -- pelvic organ prolapse -- prevalence; Menopause -- Periodicals; Menopause -- Hormone therapy -- Periodicals; Menopause -- Periodicals; Estrogen Replacement Therapy -- Periodicals; Gynecology -- Periodicals; Societies, Medical -- Periodicals; 612.665
• DOI: 10.1080/13697137.2017.1392502
• Languages: English
• ISSNs: 1369-7137

Abstract

Abstract: Objective: This study aimed to investigate the prevalence of general anxiety disorder (GAD) among postmenopausal women with symptomatic pelvic organ prolapse (POP) and to identify its associated factors. Methods: A cross-sectional study was conducted among postmenopausal women with symptomatic POP. Sociodemographic data and medical histories were obtained. Participants completed the POP Quantification (POP-Q), the Pelvic Floor Impact Questionnaire-7 (PFIQ-7), and the Pelvic Floor Distress Inventory (PFDI-20) measures. Measures of GAD were obtained using the Generalized Anxiety Disorder-7 (GAD-7). The data were analyzed using independent sample t -tests, the Mann–Whitney U -test, χ 2 tests, Fisher's exact tests and logistic regression. Results: Of the 177 participants interviewed, 19.2% had symptoms of GAD. There were no statistically significant differences in the sociodemographic characteristics or the POP-Q stage between women with and without GAD ( p > 0.05). GAD was significantly associated with higher PFDI-20 and PFIQ-7 subscale scores ( p < 0.05). After multiple logistic regression analyses, only the PFIQ-7 subscale UIQ-7 (odds ratio = 1.025, 95% confidence interval 1.007–1.043, p = 0.005) and the PFDI-20 subscale CRADI-8 (odds ratio = 1.025, 95% confidence interval 1.004–1.047, p = 0.021), which represented the impact on quality of life from lower urinary tract symptoms and the distress caused by bowel dysfunction, were risk factors that were independently associated with GAD. Conclusions: GAD is prevalent in almost one-fifth of postmenopausal women with symptomatic POP. GAD is not associated with the severity of the POP-Q stage but is associated with higher scores for lower urinary tract and bowel dysfunction caused by POP.